# Director- Clinical Research Scientist- Gyn/Onc — Eli Lilly

- Location: Indianapolis, IN
- Posted pay: $177k–$339k/yr
- Posted: Nov 17, 2026
- Status: open (checked Nov 21, 2026)
- Apply (employer's site): https://careers.lilly.com/us/en/job/LILLUSR114562EXTERNALENUS
- Employer record: https://visajobs.io/company/eli-lilly.md

## Sponsorship history
- Tier: Employer history only
- With this exact title: 0

## Description
At Lilly, the work is demanding because patients are waiting. We unite caring with discovery to help make life better for people around the world, knowing that every decision, every detail, and every day matters. Headquartered in Indianapolis, Indiana, our over 50,000 employees around the globe take on complex challenges to discover and deliver life-changing medicines, strengthen how health is understood and managed, and support the communities we serve. This is hard, urgent, selfless work—but it’s work worth doing. If you’re driven by purpose and ready to bring your best to work that truly matters for patients, we invite you to join us.
Medical Affairs Clinical Research Scientist - Director
Organization Overview:
At Lilly, we unite caring with discovery to create medicines that make life better for people around the world, and Lilly Oncology has been delivering life-changing cancer medicines for more than 50 years. Our oncology pipeline is one of the largest in Lilly's history and spans targeted therapies, immunology, radioligand platforms, and cell therapy. The Clinical Research Scientist (CRS) is the scientific engine of Lilly's oncology work — advancing evidence generation strategy, owning scientific content quality, and driving external scientific engagement. This role is designed for scientists who operate at the intersection of deep clinical knowledge, strategic thinking, and execution discipline.
Responsibilities:
The OBU Medical Affairs CRS generates, shapes, and disseminates the science connecting Lilly's oncology assets to the clinical community,
Core Expectations
Scientific Command: Maintain current, defensible command of the assigned disease area, evidence base, and competitive landscape — credible in any substantive scientific exchange.
Workstream Ownership: Own assigned workstreams end-to-end — anticipate gaps, resolve ambiguity, and drive deliverables without waiting to be directed.
Content Integrity: Uphold scientific accuracy, platform alignment, and compliance
Bias to Action: Operate with urgency — move work forward, surface risk early, and deliver on commitments.
Collaboration & Influence: Partner across Clinical Development, Medical Affairs, HEOR, External Engagement, Commercial, and field medical, to influence scientific direction without positional authority.
Evidence Generation Strategy & Execution
Translate clinical care gaps in the assigned therapeutic area into a prioritized evidence generation plan inclusive of external research collaborations, investigator initiated trials/research, and real-world data strategies that drive clinical decision-making and payer access.
Maintain evidence gap maps and align publication and disclosure plans to asset strategy, evolving HCP and payer needs, and timelines.
Partner with Clinical Development, HEOR, and Affiliates on post-approval study design, lifecycle planning, and integrated clinical-trial and real-world evidence strategies.
Drive scientific disclosure inclusive of congress abstracts, manuscripts, and plain language summaries accurately and in compliance with FDA, ICH, and Lilly SOPs.
Review independent grants and healthcare improvement initiatives in partnership with the Lilly Grants Office and Healthcare Improvement Hub.
Medical Communication & Scientific Content
Shape and contribute to the Scientific Narrative and own its consistent, current, and approved application across content, training, and engagement throughout the lifecycle
When applicable, build and deliver cross functional Innovation Readiness (i.e. environment and scientific readiness) solutions to close clinical care gaps
Develop, review, QC and execute scientific omnichannel content across the full range of Medical Affairs deliverables — publications, advisory board materials, congress presentations, HCP education, field tools, and omnichannel formats (video, infographics, plain language summaries, AI-accessible content) — built for the ecosystem through which modern HCPs engage with oncology science.
Optimize content for digital accessibility and AI readability, ensuring it is easily discoverable, interpretable, and usable by large language models (LLMs).
Ensure all content is accurate, compliant, and approved
Provide scientific input to promotional material review, and support medical information associates on reactive medical information responses — keeping both grounded in the approved platform and compliant with Lilly policies.
May include global responsibilities as the Strategic Content Lead for the team, which serves as the lead for global medical content strategy, holistic content planning, and global content pull-through across affiliate teams
HCP Engagement
Build and maintain peer-to-peer relationships with oncology thought leaders, professional societies, and HCP communities relevant to the assigned asset and indication — a network that generates actionable insights and strengthens the credibility of Lilly oncology science.
Shape the design, execution, and insight integration of scientific advisory boards, advising activities, and congress engagements for assigned workstream(s), translating strategic objectives into substantive scientific exchange.
Inform and maintain a comprehensive, disease state/therapeutic area global list of the top thought leaders in collaboration with external engagement team members
Drive strategic engagement with TLs according to this list and in collaboration with external engagement.
Partner with field medical as a scientific resource — equipping them for substantive HCP exchange and routing field insights back into evidence and communication priorities.
Scientific Intelligence & Therapeutic Landscape
Maintain deep, current expertise in disease biology, clinical landscape, treatment guidelines, competitive data, and payer/HTA standards for the assigned area, and translate it into implications for evidence and content strategy — including how global HTA bodies (EMA, NICE, HAS, CADTH) shape the evidence needed for 

> History, not a promise: past H-1B filings do not mean an employer will sponsor you or a given role. Data: U.S. DOL OFLC LCA disclosure (FY2024–FY2026 for role counts, certified LCAs) and the USCIS H-1B Employer Data Hub. Not legal advice. Methodology: https://visajobs.io/methodology
